The End Game

AI is already changing lab diagnostics - but not where most people think. The real wins are happening in reimbursement, prior auth, claim support, data reporting, and clinical trial workflows, while the flashier promise of AI-assisted pathology is still moving much slower than the sales pitches suggest.Melissa Butterworth cuts through the hype and zeroes in on what lab leaders, hospital executives, and advisors need to know before signing on to another AI vendor promise. If you are trying to decide whether AI is a true operational partner or just the latest cost-centered buzzword, this episode gives you the signal inside the noise.You will hear why AI adoption is gaining traction fastest in the back office, where ROI is immediate and measurable, and why pharma and biotech-facing labs are using AI to streamline patient recruitment and sample handling. You will also hear where the technology is still stuck, what vendors often leave out about digital pathology, and why data privacy and governance need real answers, not marketing language.Melissa also breaks down the cultural barrier that can make or break an implementation: when hospital leadership treats the lab like a cost center instead of a strategic asset, even the smartest tools struggle to get funded, supported, and scaled. She explains how lab leaders can strengthen the business case, refine workflows around the tool, and communicate upward to the C-suite in a way that gets attention.If you are evaluating AI for a lab, advising a health system, or trying to understand where this technology is actually delivering value today, this is essential listening. The episode leaves you with a sharper framework for separating real progress from hype, and for asking the questions that matter before the budget is decided.

PAMA is not "fixed," and the next real hit to lab reimbursement is closer than most executives think. Melissa Butterworth breaks down why the 2027 cliff is still ahead, why another easy congressional rescue may be less likely than before, and what lab leaders need to do right now to protect revenue.The headline everyone heard was "delay." The more important story is what Congress actually pushed back, what remains scheduled for 2027, 2028, and 2029, and why the reporting window opening in 2026 matters far more than a temporary patch. Melissa explains the latest legislative changes, the shifting CBO scoring problem that makes another one-year delay harder to pass, and why the industry conversation has moved from "Will we get another rescue?" to "What happens if we don't?"You'll discover:

• What PAMA really is and how prior rounds of cuts removed billions from the lab industry
• Why the 2026 reporting window directly impacts 2027 Medicare rates
• How the pending cuts could reach up to 15% on more than 800 laboratory procedures
• What the Results Act would change if it becomes law
• Why modeling revenue exposure now is no longer optional for outreach labs, hospital labs, and clinical labs

Melissa also walks through the practical stakes for advisors and lab executives, including how to prepare clients for the possibility that the safety net Congress has relied on seven times may not appear again. If you are responsible for lab revenue, reimbursement strategy, or client advisory conversations, this episode gives you the urgency and the framework to act before the next deadline hits.
Melissa Butterworth
is the host of Endgame Insiders on Your Side and a senior voice in the medical lab industry. She brings a clear-eyed, advisory perspective to one of the most urgent reimbursement issues facing labs today.Perfect for lab executives, outreach leaders, consultants, and anyone who needs to understand what PAMA really means for 2027 and beyond.

Melissa Butterworth discusses the potential pitfalls of outsourcing a laboratory, highlighting the importance of careful consideration and strategic planning. She emphasizes the need for hospital executives to ask critical questions before making the decision to outsource.

Takeaways

• Outsourcing can solve real problems for systems that lack the scale to run a competitive lab alone.
• Hospital executives should consider the long-term implications and have a detailed operational plan for rebuilding in-house if the outsourcing relationship doesn't work out.

Chapters

• 00:00 Introduction and Fun Fact
• 00:58 Becoming a Godmother and Return to the Episode
• 01:28 The Outsourcing Trap
• 01:55 Why Hospitals Outsource Labs
• 02:53 The Downstream Effects of Outsourcing
• 03:52 Costly Consequences of Poorly Structured Outsourcing
• 04:48 Critical Questions for Hospital Executives
• 06:14 Final Thoughts and Contact Information

In this episode of the End Game Podcast, host Melissa Butterworth discusses her personal journey in the laboratory diagnostic space and delves into the complexities of Alzheimer's disease. She highlights the current state of treatments, including anti-amyloid therapies, and emphasizes the importance of early diagnosis. The conversation shifts to lifestyle interventions that can support cognitive health, such as exercise, nutrition, and social engagement. Finally, Melissa encourages proactive approaches to improve the quality of life for those affected by Alzheimer's, urging listeners to seek community support and professional guidance.

The future of Alzheimer's diagnosis is here—and it's happening with a simple blood test.

In this episode, we explore how blood-based biomarkers are transforming the detection and management of Alzheimer's disease. Learn how innovative tests measuring biomarkers like P-TAU217 are providing highly accurate, less invasive alternatives to traditional PET scans and cerebrospinal fluid testing, making earlier diagnosis more accessible than ever.

We also discuss the critical role clinical laboratories play in implementing these advanced diagnostic technologies, the infrastructure required to support high-sensitivity testing, and how labs are helping monitor the effectiveness and safety of emerging Alzheimer's therapies. As personalized medicine continues to evolve, laboratory diagnostics are becoming an essential part of improving patient outcomes and supporting long-term disease management.

In this episode, you'll learn:

• How blood-based biomarkers are changing Alzheimer's diagnosis
• Why P-TAU217 is emerging as a key diagnostic marker
• The shift from imaging to serum-based testing
• Laboratory challenges and opportunities in high-sensitivity diagnostics
• How blood tests are supporting personalized treatment monitoring for Alzheimer's patients

Whether you're a laboratory professional, healthcare leader, or simply interested in the latest advancements in diagnostic medicine, this episode offers valuable insights into one of the fastest-growing areas of laboratory innovation.

Melissa Butterworth shares her personal journey and introduces the topic of lab future and trends. She discusses the integration of labs, the role of AI and automation, the importance of data foundation, regulatory challenges, and the shift towards sustainability as a metric in the lab industry.

Takeaways

• Integration is the key trend in the lab industry.
• Sustainability has become a mandatory KPI for labs in 2026.

Chapters

• 00:00 Introduction and Personal Journey
• 01:22 Lab Future and Trends
• 01:52 AI and Automation in Labs
• 02:19 Data Foundation and AI Initiatives
• 03:17 Regulatory Tightrope
• 04:32 Sustainability as a Metric

In this episode, Melissa Butterworth discusses the strategic timing for selling your laboratory, emphasizing preparation, market conditions, and personal readiness. Perfect for lab owners considering exit strategies, this episode offers actionable insights to maximize value.

In this episode of The End Game, Melissa Butterworth shares practical strategies for turning wellness into a daily habit through consistent tracking and small, intentional adjustments. She highlights how monitoring key areas like sleep, energy, and stress can reveal patterns over time, enabling more proactive and informed decisions. Ultimately, the episode underscores that prioritizing daily wellness not only improves overall health but also enhances focus, energy, and leadership performance.

In this episode of The End Game, Melissa Butterworth explores the strategic timing behind selling a laboratory, highlighting the key factors that can significantly impact valuation. She discusses the importance of thorough preparation, maintaining strong operational performance, understanding market conditions, and assessing personal readiness. The episode underscores that a successful exit isn’t just about when you sell—but how well-positioned your business is when you do

In this episode of The End Game podcast, host Melissa Butterworth shares her personal experience with telemedicine, specifically focusing on the Call On Doc app. She discusses the convenience and accessibility of virtual consultations, highlighting the app's features, pricing, and user satisfaction. The conversation emphasizes the growing importance of telemedicine in providing quick and efficient healthcare solutions, especially for non-emergency situations.